title: Disease-free survival following high dose or standard dose therapy in patients with amyloidosis.
authors: Department of Pharmacy, Indiana University Health Simon Cancer Center, Indianapolis, IN, USA. pkiel@iuhealth.org.
authors: Patrick J
authors: PJ
authors: Kiel
authors: Department of Pharmacy, Indiana University Health Simon Cancer Center, Indianapolis, IN, USA.
authors: Anne O
authors: AO
authors: Trueg
authors: Department of Pharmacy, Indiana University Health Simon Cancer Center, Indianapolis, IN, USA.
authors: Meagan
authors: M
authors: Ferguson
authors: Indiana University School of Medicine, Indianapolis, IN, USA.
authors: Merrill
authors: M
authors: Benson
authors: Indiana University School of Medicine, Indianapolis, IN, USA.
authors: Rafat
authors: R
authors: Abonour
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000686:Amyloidosis / Q000188:drug therapy / Q000401:mortality* / Q000628:therapy; D000069286:Bortezomib / Q000627:therapeutic use; D018572:Disease-Free Survival; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods / Q000401:mortality; D006801:Humans; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D012189:Retrospective Studies; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D000069286:Bortezomib; D008558:Melphalan
keywords: autologous haematopoietic cell rescue; bortezomib; melphalan; treatment related mortality